Latest Strategy Changes News

Carnarvon Energy has locked in the Transocean Equinox rig for a pivotal 2027 drilling campaign targeting major prospects in the Bedout Sub-basin, with costs comfortably covered by its strong cash reserves.

Vection Technologies secures a $3.3 million order from Media Comunicazione for its Accessibility Kiosk platform, adding a third profitable revenue stream to its FY26 momentum alongside defence and AI businesses.

Orange Minerals NL has agreed to sell its 51% interest in the Calarie Project tenements to Adavale Resources, receiving shares and options in return. This move supports Orange Minerals' focus on its core gold projects in Ghana and Western Australia.

Canadian Phosphate (ASX: CP8) is raising up to AUD 4.85 million via a renounceable rights issue at a 22% discount, aiming to accelerate development of its newly acquired Diamond Mountain Project in Utah and advance exploration in Canada.

Venus Metals has sold its 1% Youanmi gold royalty to Franco-Nevada for $46 million, triggering plans for $35 million in special dividends and an in-specie distribution of Rox shares to shareholders.

Findi Limited surged revenue by 36% to $83 million for FY26 but posted a hefty $52.6 million net loss, weighed down by integration costs and capital delays. The company completed a major consolidation of its Indian financial infrastructure assets and secured $25 million in fresh capital to support growth and liquidity.

Evion Group has increased the size of its second tranche placement, lifting total capital raised to A$7.24 million through the issue of over 241 million shares at 3 cents each. The second tranche awaits shareholder approval at a July meeting, including director participation and free attaching options.

IDP Education (ASX:IEL) has responded to an ASX price query following a sharp share price fall and increased trading volume, attributing the movement to a late analyst downgrade and confirming compliance with continuous disclosure rules.

Third Age Health Services posted a 17.9% revenue increase and 24.7% profit rise for FY26, driven by strategic acquisitions and expansion in aged residential care services.

Amplia Therapeutics reported encouraging mature data from its ACCENT pancreatic cancer trial showing improved survival and response rates with narmafotinib. The company raised $27.5 million to fund development and manufacturing scale-up, while discontinuing a parallel trial due to chemotherapy toxicity.

Excite Technology Services lifted revenue by 74% to $21.3 million in FY26 but still recorded a $5.4 million loss, with auditors flagging material uncertainty over its ability to continue as a going concern.

Burger Fuel Group reported a 91.8% surge in net profit to NZD 1.97 million for FY26, driven by sales growth, reduced legal costs, and a one-off store sale gain, despite geopolitical headwinds in the Middle East.